GlassScriptPhysician profile
Allan W Cass
NPI 1609889203
$705.09
in general payments reported to CMS, 2019-2025
16 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $59.03 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $231 · Food and Beverage: $39.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $231.48 |
| Food and Beverage | $39.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $254.92 | 2025 | Carvykti |
| Astrazeneca Pharmaceuticals LP | $93.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.29 | 2019 | |
| Pfizer INC. | $48.43 | 2019-2020 | |
| Verastem, INC. | $39.30 | 2019 | |
| Lilly USA, LLC | $35.57 | 2019-2020 | |
| Janssen Biotech, INC. | $30.67 | 2019 | |
| Genzyme Corporation | $25.56 | 2019-2020 | |
| Amgen INC. | $20.64 | 2019 | |
| Taiho Oncology, INC. | $20.10 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $17.73 | 2020 | |
| Stemline Therapeutics INC. | $16.14 | 2025 | Orserdu |
| Helsinn Therapeutics (U.S.), INC. | $14.51 | 2019 | |
| Tactile Systems Technology INC | $13.55 | 2019 | |
| Genentech USA, INC. | $13.21 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Cass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.